NCT07436455 F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
| NCT ID | NCT07436455 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara University |
| Condition | Thyroid Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-11-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.
Eligibility Criteria
Inclusion Criteria: * Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy * Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up * Negative or equivocal I-131 whole-body scan findings * Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status) * Giving written informed consent Exclusion Criteria: * Age under 18 years * Pregnancy or breastfeeding * Failure to provide written informed consent
Contact & Investigator
Mine Araz, Assoc.Prof.
PRINCIPAL INVESTIGATOR
Ankara University Medical School Nuclear Medicine Department
Frequently Asked Questions
Who can join the NCT07436455 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436455 currently recruiting?
Yes, NCT07436455 is actively recruiting participants. Contact the research team at minesoylu@yahoo.com for enrollment information.
Where is the NCT07436455 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07436455 clinical trial?
NCT07436455 is sponsored by Ankara University. The principal investigator is Mine Araz, Assoc.Prof. at Ankara University Medical School Nuclear Medicine Department. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.